Bio-Techne Corporation (TECH) Fair Value & Analysis
Healthcare · US · Market cap $8.3B
Bio-Techne Corporation
TECH · US
Fair value as of: Jun 24, 2026
From 24 valuation models · updated 5 days ago
Share price +37.2% over the past month.
Price vs Fair Value (12 months)
12‑month range $34.30 – $56.46 · fair‑value band $7.74 – $12.89 · the $56.26 price screens above the $10.31 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Bio-Techne Corporation (TECH) currently trades at $56.26, while our model-based Fair Value estimate is $10.31 — implying the stock looks roughly 81.7% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Bio-Techne Corporation generated revenue of $1.2B at a net margin of 9.1%. Revenue declined 1.5% year over year. It earns a return on equity of 5.3%. Net debt stands at $282M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated di…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Bio-Techne Corporation reported revenue of $1.2B in FY2025 versus $931M in FY2021, a compound +7.0%/yr. Reported net income was $73.4M in FY2025, compounding −15.0%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$582.92 | R$95.50 | -84% |
| Regeneron Pharmaceuticals, Inc REGN | $612.50 | $1,280 | +109% |
| UCB SA UCB | €274.90 | €211.40 | -23% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $286.41 | $106.81 | -63% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Bio-Techne Corporation (TECH) undervalued?
What is the fair value of TECH?
What is the quality score of TECH?
What is the revenue of Bio-Techne Corporation (TECH)?
What is the net profit margin of TECH?
Does Bio-Techne Corporation pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.